



Innovative Medicines Initiative


Achievements and Opportunities

Michel Goldman, MD, PhD
Executive Director




efpia

Innovative Medicines Initiative: *Joining Forces in the Healthcare Sector*



A Typical IMI Consortium



IMI Executive Office as a Neutral Third-Party



- Ensures that projects are carried out in the common interest of all stakeholders
- Guarantees fair conditions for knowledge exploitation and dissemination
- Facilitates the dialog between industry, patients' organizations and regulatory agencies



Calls 1 & 2: *Consolidated Figures*



	Total
Projects (N)	23
EFPIA Companies (N)	23
Academic teams (N)	298
SME teams (N)	47
Patients' organizations (N)	11
Regulatory agencies (N)	6
Budget (M€)	453



NEWMEDS




Develops biomarkers and tools and models to allow better targeted treatments for schizophrenia and depression

19 Partners

- 9 EFPIA companies
- 7 Public organisations
- 3 SMEs

First achievements

- ✓ Has assembled the largest known repository of antipsychotic clinical trial data.
- ✓ The database contains information on 23 401 patients from 67 industry sponsored studies.
- ✓ Bringing together data from public projects and 3 companies on the genetics and clinical response in 1800 well characterized patients with depression.



Nature, 11 November 2010



efpia


Paves the way towards a *new classification of asthma* and personalized treatments for patients

38 Partners

- 9 EFPIA companies
- 23 Academic institutions
- 3 Patients' organizations
- 3 SMEs

First achievements


- ✓ A new stepwise algorithm for the stratification of patients with severe asthma



Thorax, in press



PRO-ACTIVE



PRO-ACTIVE



Activity Monitor


Amount of activities



PDA for E-PRO

Symptoms / other dimensions

Symptoms / PA
Adaptations



Time (days)



Addresses the current lack of sensitive and specific clinical tests to diagnose and monitor drug-induced injury to the kidney, liver and vascular tissues in man, which is a major hurdle in drug development

20 Partners

- 11 EFPIA Pharma Companies
- 5 Academic Institutions
- 4 SMEs

First achievements

- ✓ 153 potential biomarker candidates for drug-induced injury of the kidney, liver and vascular system have been evaluated and are currently undergoing clinical evaluation.
- ✓ The strategy adopted has been agreed with the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA).

A generic operational strategy to qualify translational safety biomarkers

Katja Matheis¹, David Laurie², Christiane Andriamandroso³, Nadir Arber⁴, Lina Badimon⁵, Xavier Benain⁶, Kaidre Bendjama⁷, Isabelle Clavier⁶, Peter Colman⁸, Hüseyin Firat⁷, Jens Goepfer⁹, Steve Hall⁸, Thomas Joos¹⁰, Sarah Kraus⁴, Axel Kretschmer¹¹, Michael Merz², Teresa Padro⁵, Hannes Planatscher⁹, Annamaria Rossi⁸, Nicole Schneiderhan-Marra⁹, Ina Schuppe-Koistinen¹², Peter Thomann⁷, Jean-Marc Vidal¹³ and Béatrice Molac⁷

¹Boehringer-Ingelheim Pharma GmbH & Co. KG, Biberach, Germany

²Novartis Pharma AG, Basel, Switzerland

³Interface Europe, Brussels, Belgium

⁴Tel-Aviv (Souraski) Medical Center, Tel-Aviv, Israel

⁵Barcelona Cardiovascular Research Center (ICCC-CISC), Barcelona, Spain

⁶Sanofi-Aventis, Paris, France

⁷Firalis SAS, 35 rue du Fort, 68330 Huningue, France

⁸Pfizer Ltd, Sandwich, UK

⁹Natural and Medical Sciences Institute, Reutlingen, Germany

¹⁰Experimental & Diagnostic Immunology GmbH, Reutlingen, Germany

¹¹Bayer Schering Pharma AG, Leverkusen, Germany

¹²AstraZeneca R&D, Södertälje, Sweden

¹³EMA, London, UK

Drug Discov Today, in press



Builds a large searchable database containing drug toxicity-related data extracted from relevant pharmaceutical pre-clinical legacy reports


Develops innovative methodological strategies and novel software tools to better predict in silico the toxicological profiles of new molecular entities in early stages of the drug development pipeline, using its database background

25 Partners

- 13 EFPIA companies
- 8 Public organisations
- 4 SMEs

First achievements

- ✓ An innovative multi-scale modelling strategy for the prediction of cardiotoxicity has been developed, successfully tested and published



J. Chem. Inf. Model. 2011; 51:483-92



IMI Education & Training Programmes



www.imi.europa.eu

**IMI EDUCATION AND
TRAINING PROGRAMMES**

- ✓ First course in Nov 2010 on drug discovery development
- ✓ Certificate and Master courses in pharmacovigilance and pharmacoepidemiology in Sept 2011
- ✓ EU syllabus on pharmaceutical medicine
- ✓ Database on over 700 master courses, 110 professional development courses, 380 learning tools




Projects under elaboration (3rd Call)



- Early prediction of drug-induced liver injury
- Risk minimization of antibodies to biopharmaceuticals
- Immunosafety of vaccines
- Translational research on autism spectrum disorders
- Personalized medicine in type II diabetes
- New strategies to treat tuberculosis
- Patient awareness on pharmaceutical innovation



A Multidimensional Mission



Pozen R, Kline H, Science Translational Med 2011, 3: 1-5





Innovative Medicines Initiative

www.imi.europa.eu

THANK YOU !



efpia*